[The expression and clinical significance of Annexin  II  in clear-cell renal cell carcinoma].
OBJECTIVE
To discuss the difference of annexinII expression between the Clear-Cell Renal Cell Carcinoma(ccRCC) and the corresponding normal renal tissues,  and to reveal the clinical significance of Annexin II expression in ccRCC.


METHODS
Western blotting  was used to detect the expression of Annexin  II in 29 samples of fresh ccRCC and the corresponding normal renal tissues.  Annexin  II expression was examined in 120 samples of paraffin-embedding ccRCC and the corresponding normal renal tissues using immunohistochemistry. Correlations with Annexin  IIexpression and clinic-pathological parameters were analyzed.


RESULTS
There was expression of Annexin  II in both ccRCC and the corresponding normal renal tissues. In ccRCC tissues,  the total levels of Annexin  II proteins were significantly higher than that in the corresponding normal renal tissues (P<0.01). The positive rate of AnnexinII expression in immunohistochemistry was 67.5% in the ccRCC tissues,  existing significant difference compared with the corresponding normal renal tissues (P<0.01).  Expression of Annexin  II  in ccRCC mainly showed membranous staining. Annexin II expression level was positively correlated with TNM stage (P<0.05),  histology grade (P<0.05),  renal capsule infiltration (P<0.01) and distant metastasis (P<0.01) of ccRCC. Moreover,  Annexin  II expression level was significantly correlated with ccRCC patients'5-years survival rate(P<0.01).


CONCLUSIONS
Overexpression of AnnexinII in the ccRCC is closely correlated with the ccRCC development. It may play an important role in the process of ccRCC invasion and metastasis.
Department of Medical Oncology, the First Affiliated Hospital, Medical College of Xian Jiaotong University, Xian 710061, China.
Jin
J
Yang
Ting-ting
TT
Cheng
Li-na
LN
Wang
Wei
W
Chen
Xu
X
Li
D000328:Adult; D000368:Aged; D017306:Annexin A2 / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis
D017306:Annexin A2